Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-30
2011-12-20
Gibbs, Terra Cotta (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
08080531
ABSTRACT:
ATR kinase is a key regulator of checkpoint responses to incompletely replicated and damaged DNA. Without this checkpoint, cells will enter mitosis prematurely, likely resulting in cell death. The invention provides methods and reagents to either block or activate the activation of the ATR kinase checkpoint, through, for example, either blocking or activating the expression of an ATR activator TopBP1. The invention also provides screening methods to identify additional ToBP1 inhibitors or activators that may be used to modulate the activity of the ATR checkpoint.
REFERENCES:
GenBank Accession No. BAA34202 (published Nov. 6, 1998).
Yamane et al. Eur. J. Biochem. 250 (3) 794-799 (1997).
Yamane et al. Cancer Research, 2003 vol. 63:3049-3053.
Yamane et al. Molecular and cellular Biology, 2002 vol. 22:555-566.
Lu et al. (2005) in RNA Interference Technology (Cambridge, Appasani, ed.).
Downward, J. BMJ, 2004 vol. 328:1245-1248.
Braasch et al. Biochemistry, vol. 41, pp. 4503-4510.
Yoo, et al., “Ataxia-telangiectasie Mutated (ATM)-dependent Activation of ATR Occurs through Phosphorylatin of TopBP1 by ATM,” Journal of Biological Chemisry 282(24):17501-17506 (2007).
Ball, et al., “Function of a Converved Checkpoint Recruitment Domain in ATRIP Proteins,” Molecular and Celluar Biology 27(9): 3367-3377 (2007).
Kumagia, et al., “TopBP1 Activates the ATR-ATRIP Complex,” Cell 124:943-955 (2006).
Corez, et al., “ATR and ATRIP: Partners in Checkpoint Signaling,” Science 294:1713-1716 (2001).
Kim, et al, “Human TipBP1 Ensures Genome Integrity During Nornal S Phase,” Molecular and Cellular Biology, 25(24):10907-10915, (2005).
Braasch, et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,” Biochemistry, vol. 41 No. 14, pp. 4503-4509, (2002).
Downward, J. “Science, medicine, and the future RNA Interference,” BMJ vol. 328, pp. 1245-1248; May 22, 2004.
Lu, et al., “Delivering sIRNA in vivo for functional genomics and novel therapeutics,” RNA Interference Technology (Cambridge, Appasani, ed.), pp. 303-317, (2005).
Yamane, et al., “A DNA Damage-Regulated BRCT-Containing protein, TopBP1, Is Required for Cell Survival,” Molecular and Cellular Biology, vol. 22, No. 2, pp. 555-566, Jan. 2002.
Yamane, et al., “Both DNA Topoisomerase II-binding Protein 1 and BRCA1 Regulate the G2-M Cell Cycle Checkpoint,” Cancer Research, vol. 63, 3049-3053, Jun. 15, 2003.
Dunphy William
Kumagai Akiko
California Institute of Technology
Gibbs Terra Cotta
Ropes & Gray LLP
LandOfFree
Methods for modulating checkpoint activation through TopBP1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating checkpoint activation through TopBP1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating checkpoint activation through TopBP1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270903